Feature | April 08, 2014

GE Healthcare Receives FDA for Q.Clear PET/CT Technology

Technology can enable clinicians to assess patient's response to treatment accurately

GE Healthcare Q.Clear Technology PET/CT Systems Nuclear Imaging

April 8, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Q.Clear technology, which is designed to provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. 

Over the last decade, positron emission tomography (PET) image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as time of flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare said its Q.Clear technology brings convergence to PET imaging without the need for compromise between quantitation and image quality.

"Q.Clear is a major step forward because it can give us a consistent and reliable measurement when determining whether the current course of a patient's cancer treatment is effective," said Dr. Gustav von Schulthess, nuclear medicine chair at University Hospital Zurich. "It will give the oncologist more confidence because if a change of therapy is needed, you want accurate information early on to best adjust treatment for the patient."

Clinicians not only want the ability to detect smaller lesions, but the ability to determine earlier whether the patient is responding to current treatment. Q.Clear aims to help in both areas by providing better quantitation accuracy for truly personalized medicine. Coupled with Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear can enable clinicians to assess treatment response accurately.

"We know that approximately 70 percent of cancer patients don't always respond to their initial course of treatment," said Steve Gray, president and CEO of GE Healthcare MICT. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/computed tomography (CT) can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures.  Q.Clear gives clinicians the ability to help make that determination."

GE said the system may not be available for sale in all regions. For countries that require CE marking, Q.Clear is not yet CE marked.

For more information: www3.gehealthcare.com

Related Content

Technology | PET Imaging

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ...

Home December 05, 2018
Home
News | PET Imaging

July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new ...

Home July 17, 2018
Home
News | PET Imaging

July 7, 2017 — Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are ...

Home July 07, 2017
Home
News | PET Imaging

March 3, 2017 — In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers ...

Home March 03, 2017
Home
News | PET Imaging

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular ...

Home September 01, 2016
Home
Feature | PET Imaging | Dave Fornell

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables ...

Home June 03, 2016
Home
News | PET Imaging

September 23, 2015 — New research describes a method, tested in rats, that may someday allow healthcare providers to ...

Home September 23, 2015
Home
Subscribe Now